Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice

Antiviral Research

Volumn 140, Issue , 2017, Pages 55-61

  Wang, Chong ^a,b   Zheng, Xuexing ^c   Gai, Weiwei ^a,d   Wong, Gary ^e   Wang, Hualei ^a,f   Jin, Hongli ^a   Feng, Na ^a,f   Zhao, Yongkun ^a,f   Zhang, Weijiao ^a,d   Li, Nan ^a   Zhao, Guoxing ^a   Li, Junfu ^e   Yan, Jinghua ^e   Gao, Yuwei ^a,f   Hu, Guixue ^g   Yang, Songtao ^a,f   Xia, Xianzhu ^a,f  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

^c SHANDONG UNIVERSITY   (China)

^d JILIN UNIVERSITY   (China)

^e INSTITUTE OF MICROBIOLOGY   (China)

^f YANGZHOU UNIVERSITY   (China)

^g JILIN AGRICULTURAL UNIVERSITY   (China)

Author keywords

CPV; Immune response; Middle East respiratory syndrome coronavirus; Receptor binding domain; Virus like particles

Indexed keywords

CANINE PARVOVIRUS VP2 STRUCTURE PROTEIN; CHIMERIC VIRUS LIKE PARTICLE VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS RECEPTOR; NEUTRALIZING ANTIBODY; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VIRUS VACCINE; CAPSID PROTEIN; CYTOKINE; IMMUNOLOGICAL ADJUVANT; PROTEIN BINDING; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANINE PARVOVIRUS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHROCYTE; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN DOMAIN; SPLEEN CELL; VIRUS PARTICLE; ANIMAL; BLOOD; CHIMERA; CORONAVIRUS INFECTION; GENETICS; IMMUNOLOGY; PIG; SECRETION (PROCESS); TH1 CELL; TH2 CELL; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CHIMERA; CORONAVIRUS INFECTIONS; CYTOKINES; ERYTHROCYTES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PARVOVIRUS, CANINE; PROTEIN BINDING; SWINE; TH1 CELLS; TH2 CELLS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 85009968378     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.12.019     Document Type: Article

References (38)

1. Barcena, J., Blanco, E., Design of novel vaccines based on virus-like particles or chimeric virions. Subcell. Biochem. 68 (2013), 631–665.
2. Casal, J.I., Rueda, P., Hurtado, A., Parvovirus-like particles as vaccine vectors. Methods 19:1 (1999), 174–186.
3. Clinical Trials.gov, Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers. 2016.
4. Coleman, C.M., Liu, Y.V., Mu, H., Taylor, J.K., Massare, M., Flyer, D.C., et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32:26 (2014), 3169–3174.
5. Cullen, L.M., Blanco, J.C., Morrison, T.G., Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J. Transl. Med., 13(1), 2015, 350.
6. Du, L., Zhao, G., Kou, Z., Ma, C., Sun, S., Poon, V.K., et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 87:17 (2013), 9939–9942.
7. Du, L., Kou, Z., Ma, C., Tao, X., Wang, L., Zhao, G., et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One, 8(12), 2013, e81587.
8. Feng, H., Hu, G.Q., Wang, H.L., Liang, M., Liang, H., Guo, H., et al. Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity. PLoS One, 9(1), 2014, e79575.
9. Gilbert, L., Toivola, J., Lehtomäki, E., Donaldson, L., Käpylä, P., Vuento, M., et al. Assembly of fluorescent chimeric virus-like particles of canine parvovirus in insect cells. Biochem. Biophys. Res. Commun. 313:4 (2004), 878–887.
10. Gilbert, L., Toivola, J., Valilehto, O., Saloniemi, T., Cunningham, C., White, D., et al. Truncated forms of viral VP2 proteins fused to EGFP assemble into fluorescent parvovirus-like particles. J. Nanobiotechnol., 4, 2006, 13.
11. Grgacic, E.V., Anderson, D.A., Virus-like particles: passport to immune recognition. Methods 40:1 (2006), 60–65.
12. Ichinohe, T., Watanabe, I., Ito, S., Fujii, H., Moriyama, M., Tamura, S., et al. Synthetic double-stranded RNA poly(I: C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79:5 (2005), 2910–2919.
13. Kim, E., Okada, K., Kenniston, T., Raj, V.S., AlHajri, M.M., Farag, E.A., et al. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine 32:45 (2014), 5975–5982.
14. Lan, J., Deng, Y., Chen, H., Lu, G., Wang, W., Guo, X., et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One, 9(11), 2014, e112602.
15. Lan, J., Yao, Y., Deng, Y., Chen, H., Lu, G., Wang, W., et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine 2:10 (2015), 1438–1446.
16. Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 25:11 (2015), 1237–1249.
17. Lo-Man, R., Rueda, P., Sedlik, C., Deriaud, E., Casal, I., Leclerc, C., A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur. J. Immunol. 28:4 (1998), 1401–1407.
18. Lopez de Turiso, J.A., Cortes, E., Martinez, C., Ruiz de Ybanez, R., Simarro, I., Vela, C., et al. Recombinant vaccine for canine parvovirus in dogs. J. Virol. 66:5 (1992), 2748–2753.
19. Martinez, C., Dalsgaard, K., Lopez de Turiso, J.A., Cortes, E., Vela, C., Casal, J.I., Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine 10:10 (1992), 684–690.
20. Maughan, C.N., Preston, S.G., Williams, G.R., Particulate inorganic adjuvants: recent developments and future outlook. J. Pharm. Pharmacol. 67:3 (2015), 426–449.
21. Miyamura, K., Kajigaya, S., Momoeda, M., Smith-Gill, S.J., Young, N.S., Parvovirus particles as platforms for protein presentation. Proc. Natl. Acad. Sci. U. S. A. 91:18 (1994), 8507–8511.
22. Modjarrad, K., MERS-CoV vaccine candidates in development: the current landscape. Vaccine 34 (2016), 2982–2987.
23. Mou, H., Raj, V.S., van Kuppeveld, F.J., Rottier, P.J., Haagmans, B.L., Bosch, B.J., The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87:16 (2013), 9379–9383.
24. Muthumani, K., Falzarano, D., Reuschel, E.L., Tingey, C., Flingai, S., Villarreal, D.O., et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci. Transl. Med., 7(301), 2015 301ra132.
25. Okada, H., Kalinski, P., Ueda, R., Hoji, A., Kohanbash, G., Donegan, T.E., et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-cytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29:3 (2011), 330–336.
26. Perera, R.A., Wang, P., Gomaa, M.R., El-Shesheny, R., Kandeil, A., Bagato, O., et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill. Bull. Eur. les Mal. Transm. = Eur. Commun. disease Bull., 18(36), 2013 pii=20574.
27. Rahimian, S., Fransen, M.F., Kleinovink, J.W., Christensen, J.R., Amidi, M., Hennink, W.E., et al. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation. J. Control Release 203 (2015), 16–22.
28. Rueda, P., Hurtado, A., del Barrio, M., Martinez-Torrecuadrada, J.L., Kamstrup, S., Leclerc, C., et al. Minor displacements in the insertion site provoke major differences in the induction of antibody responses by chimeric parvovirus-like particles. Virology 263:1 (1999), 89–99.
29. Schmidt, M.R., McGinnes-Cullen, L.W., Kenward, S.A., Willems, K.N., Woodland, R.T., Morrison, T.G., Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory. J. Virol. 88:17 (2014), 10165–10176.
30. Slifka, M.K., Amanna, I., How advances in immunology provide insight into improving vaccine efficacy. Vaccine 32:25 (2014), 2948–2957.
31. Song, F., Fux, R., Provacia, L.B., Volz, A., Eickmann, M., Becker, S., et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 87:21 (2013), 11950–11954.
32. van Doremalen, N., Munster, V.J., Animal models of Middle East respiratory syndrome coronavirus infection. Antivir. Res. 122 (2015), 28–38.
33. Volz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J. Virol. 89:16 (2015), 8651–8656.
34. Wang, L., Shi, W., Joyce, M.G., Modjarrad, K., Zhang, Y., Leung, K., et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun., 6, 2015, 7712.
35. Wang, C., Zheng, X., Gai, W., Zhao, Y., Wang, H., Wang, H., et al. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget, 2016 (in press).
36. Xu, J., Guo, H.C., Wei, Y.Q., Dong, H., Han, S.C., Ao, D., et al. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine. Appl. Microbiol. Biotechnol. 98:8 (2014), 3529–3538.
37. Ye, X., Ku, Z., Liu, Q., Wang, X., Shi, J., Zhang, Y., et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J. Virol. 88:1 (2013), 72–81.
38. Zhao, G., Du, L., Ma, C., Li, Y., Li, L., Poon, V.K., et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virology J., 10, 2013, 266.